While a reduction of SIPL1 mRNA in stage IV breast cancers was observed in the largest dataset (Curtis), only 8 cases of stage IV tumors were included versus the large number of tumors of other stages (n = 257 for stage I, n = 446 for stage II, and n = 69 for stage III tumors) and called for precautious in interpretation of this decrease. This evidence concerns the gene SHARPIN and breast carcinoma.